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Objectives
Self-reported adherence assessment in HIV-infected patients on antiretroviral therapy (ART) is
challenging and may overestimate adherence. The aim of this study was to improve the ability of
health care providers to elicit patients’ reports of nonadherence using a “patient-centred” approach
in a rural sub-Saharan African setting.
Methods
A prospective interventional cohort study of HIV-infected patients on ART for ≥ 6 months attending an
HIV clinic in rural Tanzania was carried out. The intervention consisted of a 2-day workshop for health
care providers on patient-centred communication and the provision of an adherence assessment checklist
for use in the consultations. Patients’ self-reports of nonadherence (≥ 1missed ART dose/4 weeks),
subtherapeutic plasma ART concentrations (< 2.5th percentile of published population-based
pharmacokinetic models), and virological and immunological failure according to theWorld Health
Organization definition were assessed before and after (1–3 and 6–9 months after) the intervention.
Results
Before the intervention, only 3.3% of 299 patients included in the study reported nonadherence.
Subtherapeutic plasma ART drug concentrations and virological and immunological failure were
recorded in 6.5%, 7.7% and 14.5% of the patients, respectively. Two months after the intervention,
health care providers detected significantly more patients reporting nonadherence compared with
baseline (10.7 vs. 3.3%, respectively; P < 0.001), decreasing to 5.7% after 6–9 months. A time
trend towards higher drug concentrations was observed for efavirenz but not for other drugs. The
virological failure rate remained unchanged whereas the immunological failure rate decreased from
14.4 to 8.7% at the last visit (P = 0.002).
Conclusions
Patient-centred communication can successfully be implemented with a simple intervention in
rural Africa. It increases the likelihood of HIV-infected patients reporting problems with adherence
to ART; however, sustainability remains a challenge.
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Introduction
Antiretroviral treatment (ART) has dramatically decreased
rates of HIV-related morbidity and mortality, but these
effects critically depend on successful lifelong treatment.
Adherence to ART is essential for the success of HIV
treatment. Without sufficient adherence, treatment failure
is much more likely to occur, leading to avoidable HIV-
related morbidity and mortality, emergence of resistant
HIV strains and ongoing HIV transmission [1–4]. Main-
taining good adherence to ART is challenging for many
HIV-infected patients, making nonadherence a frequent
and important problem globally [5–9]. A meta-analysis of
84 observational studies from high- and low-income
countries in 2011 found that only an average of 62% of
HIV-infected patients reported a sufficient intake of
≥ 90% of the prescribed ART drugs [7].
Interventions to improve, support and sustain adher-
ence to ART are clearly needed. Adherence is crucial for
the individual but also from a public health perspective,
particularly in light of the new World Health Organiza-
tion (WHO) recommendations to treat all patients living
with HIV regardless of CD4 count and to implement
treatment as prevention [10].
Different approaches to improve adherence exist [11–
15]. They are all based upon the reliable detection of
nonadherence. Self-reported adherence is most commonly
used for adherence assessment because it is inexpensive
and easy to apply in almost all settings [16–18]. However,
self-reports tend to overestimate adherence because of
recall or social desirability bias [3,19–23].
In order to improve patients’ adherence, health care
providers must encourage patients to talk about adher-
ence problems [24–26]. Patients must feel invited to talk
about their personal views, including their perspective on
medication adherence. Elicting the patient’s perspective is
a central element of patient-centred communication [27].
This approach, advocated as a central element of high-
quality medical care mainly in western settings [28–30],
has received little attention in many low-income coun-
tries including sub-Saharan Africa where a “doctor-
centred” approach is still more commonly applied
[31,32].
The aim of this study was to examine whether a 2-day
workshop focussing on “patient-centred” communication
improves the ability of health care providers to elicit
patients’ reports of problems with adherence in the rural
setting of sub-Saharan Africa [33–35].
Methods
Study setting
Our 1-year prospective interventional cohort study was
conducted at the Chronic Diseases Clinic of Ifakara (CDCI)
at the St Francis Referral Hospital in rural Tanzania from
October 2013 until September 2014.
The CDCI is a governmental accredited HIV clinic that
provides free medical care and antiretroviral drugs for
HIV-infected patients in the framework of the Kilombero
and Ulanga Antiretroviral Cohort (KIULARCO). At the
time of the study, approximately 3000 patients at the
CDCI were taking ART. Thirteen Tanzanian health care
providers, that is, six physicians, four nurses, two adher-
ence counsellors and one pharmacist, cared for an aver-
age of 73 HIV-infected patients daily (range 36–133).
Study population
All consecutive HIV-infected patients presenting at the
CDCI between October and November 2013 fulfilling the
inclusion criteria were enrolled in the study. Inclusion
criteria were HIV-infected adult ≥ 16 years, therapy with
an efavirenz-, nevirapine-, lopinavir/ritonavir- or ataza-
navir/ritonavir-based ART regime for at least 6 months,
and provision of written informed consent. Patients on
treatment with rifampicin or other drugs potentially
inducing ART drug metabolism and patients from other
HIV clinics were excluded.
Intervention
All the Tanzanian health care providers (n = 13) with
direct patient contact, including all six HIV physicians,
received 2 days of training in the basic elements of
patient-centred communication. Goals were defined as fol-
lows: to identify patients with nonadherenence, to identify
their reasons for nonadherence, and to establish means to
improve adherence. During the workshop, participants pro-
vided descriptions of difficult patient encounters and they
identified their communication strategies when they had
detected a patient with adherence problems, usually provi-
sion of information (see Fig. S1). Then, alternatives were
offered and trained in role-plays among participants. Sem-
inars were held in December 2013 and were delivered by
an experienced communication teacher working in the HIV
field (author W. Langewitz) [33–36]. In addition, all physi-
cians received a written two-page adherence assessment
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checklist, adapted from the published European AIDS Clin-
ical Society 2011 guidelines [37], to facilitate future con-
sultations and adherence assessment (see Fig. S2).
Study evaluations
All study patients were assessed by their physicians dur-
ing their routine visits at the CDCI at three different
time-points over 1 year (Fig. 1). No additional visits were
scheduled for the study. The baseline visit (visit 1) took
place at entry into the study. The communication training
was performed shortly after completion of the baseline
visits of all included patients. Follow-up visits were
1–3 months (visit 2) and 6–9 months (visit 3) after the
intervention. Adherence, clinical parameters, comedica-
tions and laboratory HIV surrogate markers were evalu-
ated at each study visit.
Self-reported adherence was assessed by the treating
physicians using a validated short questionnaire that con-
sisted of the following two questions as per the standard
procedure in the CDCI [4,38,39]: (1) “How often have you
missed a dose of your HIV medication in the past 4 weeks:
daily, more than once a week, once a week, once every sec-
ond week, once a month, never?” and (2) “Did you miss
ART ≥ 2 days in a row in the last 4 weeks: yes or no?”
At each study visit, we carried out therapeutic drug
monitoring (TDM) by measuring the plasma ART drug
concentrations of efavirenz, nevirapine, lopinavir and
atazanavir to assess short-term adherence. Plasma sam-
ples were analysed with a validated liquid chromatogra-
phy tandem mass spectrometry method (LC-MS/MS; API
4000 QTrap; AB Sciex, Massachusetts, USA) at the
analytical laboratory of the Division of Clinical Pharma-
cology at the University Hospital Basel (Basel, Switzer-
land).
CD4 cell count and HIV RNA were measured at every
study visit. CD4 cell counts were analysed using a flow
cytometry system (FACS Calibur; BD Company, Franklin
Lakes, NJ). HIV RNA was prepared using the semi-auto-
mated extractor platform Prepito (PerkinElmer chemagen,
Baesweiler, Germany) and quantified using a validated
protocol [40] at the CDCI laboratory and a reference labo-
ratory at the University of Basel (Basel, Switzerland).
All plasma sample aliquots for HIV RNA and ART TDM
were stored at 80°C and shipped on dry ice to the refer-
ence laboratory in Switzerland for analysis.
HIV RNA and TDM results were not available to the
health care providers before visit 3 for logistical reasons.
Definitions
Self-reported nonadherence in the questionnaire was
defined as having missed at least one dose of ART medi-
cation in the last 4 weeks. We considered other less strict
definitions of nonadherence: having missed at least two
ART doses and having missed at least two consecutive
ART doses (drug holidays) in the last 4 weeks. For TDM,
an inadequate subtherapeutic drug concentration as a
marker for nonadherence was defined as any concentra-
tion below the 2.5th percentile of published population-
based pharmacokinetic models for efavirenz 600 mg once
daily [41], nevirapine 200 mg twice daily [42], lopinavir/
ritonavir 400/100 mg twice daily [43] and atazanavir/
ritonavir 300/100 mg once daily [44]. Clinical failure was
HIV RNA
TDM
Questionnaire
V1 V2
0-3m
242 (80.9%) patients with complete follow-up V1–V3
299 (100%) 291 (97.3%) 280 (93.6%)
Evaluations
294 (98.3%) 275 (92.0%) 255 (85.3%)
297 (99.3%) 286 (95.7%) 284 (95.0%)
Communication
training
CD4 count 298 (99.7%) 275 (92.0%)285 (95.3%)
+ Adherence assessment checklist for consultations
INTERVENTION
V1 V2 V3
+51–77 days
12 months
+234–260 days–40 to –18 days
Fig. 1 The study algorithm. V1, visit 1 (baseline visit); V2, visit 2; V3, visit 3; Questionnaire, self-reported adherence questionnaire; TDM, therapeutic
drug monitoring; days, days between the evaluation and the communication training (interquartile range); numbers represent numbers of patients.
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defined as the occurence of any new WHO AIDS-defining
disease, death, or loss to follow-up at visits 2 and 3. Viro-
logical failure was defined according to the WHO 2014
guidelines as a detectable HIV RNA of ≥ 1000 copies/ml.
Immunological failure was defined as a decrease in CD4
count to below the baseline value at HIV diagnosis, a fall
of > 50% from the value at the baseline study visit (visit 1),
or persistent CD4 cell count < 100 cells/ll [45].
Primary and secondary endpoints
The primary endpoint was the rate of patients’ self-
reported nonadherence, defined as at least one missed
ART dose in the last 4 weeks, detected by the physician
after the teaching intervention (visits 2 and 3) compared
with that detected at visit 1. Secondary endpoints were
the rate of patients with subtherapeutic ART drug con-
centrations and the rate of patients with virological and
immunological failure at the end of the study (visit 3)
compared with those at visit 1.
Statistical analysis
A paired t-test was performed for continuous normally
distributed data and a sign test or Wilcoxon signed-rank
test was performed for nonparametric data to test the null
hypothesis. For categorial variables, McNemar’s test was
used. A P-value < 0.05 was considered significant. A
kappa test was used to analyse the agreement between
different adherence measurements.
In accordance with the published literature [6–9], and
assuming an adherence rate of 60%, a sample size of
approximately 300 patients was calculated to be required
to detect an increase to 70% (determined by TDM) with
90% power, a = 0.05 and an estimated drop-out rate of
20%.
All analyses were performed using STATATM software ver-
sion 11 for Windows (Stata Corp, College Station, TX,
USA).
Patient data were extracted from electronic and paper-
based patient charts and anonymized before analysis.
Ethics
Research and ethical clearance was obtained from the Ifa-
kara Health Institute Institutional Review Board (IHI/IRB/
No.28-2013), the Medical Research Coordination Board of
the Tanzanian National Institute for Medical Research
(NIMR/HQIR.8a/V01.IXlI762), and the Tanzanian Commis-
sion for Science & Technology (No.2014-276-NA-2014-
195). Written informed consent was obtained from all
participants enrolled in the study.
Results
Baseline participant characteristics and clinical
outcome
Three hundred and four patients were evaluated for study
enrolment. Five patients were excluded because they were
on current tuberculosis treatment (n = 2) or had medical
care provided at another HIV clinic (n = 3). Data for a
total of 299 HIV-infected patients on ART were finally
analysed. Two hundred and 42 patients (80.9%) com-
pleted study evaluations at all three visits, including clin-
ical and self-reported adherence assessment, CD4 cell
count, viral load measurement and TDM (Fig. 1). Baseline
characteristics are summarized in Table 1. The median
age was 41 years [interquartile range (IQR) 35–48 years]
and 28.8% were male. Most patients lived < 5 km from
the CDCI (72.9%) and worked as farmers (85.9%). Two-
thirds of the patients started ART because they had WHO
stage IV disease or a CD4 cell count < 200 cells/ll. The
median CD4 count nadir was 138 cells/ll (IQR: 59–220
cells/ll) and 59.2% had WHO stage III/IV disease. Median
ART duration at baseline was 43 months (IQR: 22–
64 months). Sixty-seven per cent were taking an efavir-
enz-based and 36.8% a one-pill fixed-dose combination
ART regimen (efavirenz, tenofovir and emtricitabine or
lamivudine). Nine per cent were on a second-line pro-
tease inhibitor-based ART regimen with lopinavir/riton-
avir. One quarter of the patients had experienced at least
one episode of nonadherence prior to the study. Only
three patients reported signs of ART toxicity and one
patient was newly diagnosed with Kaposi sarcoma at the
baseline visit. Fifteen patients (5.4%) had an unfavourable
outcome over the entire study period: six patients were
diagnosed with a new AIDS-defining disease (four with
tuberculosis and two with Kaposi sarcoma), six patients
died (one from tuberculosis and five for unknown rea-
sons), and three were lost to follow-up at visits 2 and 3
(Table 2).
Self-reported adherence assessed using the
questionnaire
Only 3.3% of the patients reported nonadherence (missed
at least one ART dose in the last 4 weeks) via the ques-
tionnaire at the baseline visit (visit 1) (Table 2). The med-
ian time from the intervention to visit 2 and visit 3 was
63 (IQR: 51–77) and 246 (IQR: 234–260) days, respec-
tively. At visit 2, significantly more patients reported
problems with adherence (10.7%) compared with baseline
(P < 0.001). At visit 3, the detection rate decreased to
5.7%, which was not statistically different from that at
baseline (P = 0.201). Similar results were obtained when
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stratifying for protease inhibitor and nonnucleoside
reverse transcriptase inhibitor therapy as well as for one-
pill- and poly-pill-based ART regimens.
When alternative cut-offs were used to define nonad-
herence (at least two missed ART doses and drug holidays
in the last 4 weeks), the reported nonadherence rate was
significantly higher at visit 2 (5.5 and 2.7%, respectively)
and remained significantly higher at visit 3 (3.9 and
3.2%, respectively) compared with baseline (0.7% and
0.3%, respectively) (Table 2 and Fig. 2).
Reasons for missed ART doses were available in 28 of
the 59 patients (47%) who reported nonadherence during
the study period. The most common reasons for missed
ART doses were running out of pills (64.3%), forgetting
to take the pills (10.7%), travel problems (7.1%) and feel-
ing depressed (3.6%).
Adherence assessment by plasma ART therapeutic
drug monitoring
Plasma drug concentrations were measured for efavirenz
(n = 543), nevirapine (n = 199), lopinavir (n = 70) and
atazanavir (n = 12). Concentrationtime plots for efavir-
enz, nevirapine and lopinavir are shown in Fig. 3. The
mean time interval between last ART intake and
drug concentration measurement was 14:40 h for efavir-
enz [standard deviation (SD)  2:50 h], 13:32 h for nevi-
rapine (SD  3:46 h) and 12:48 h for lopinavir
(SD  3:13 h) and was similar at each of the three visits.
At visit 1, 6.5% of patients had a subtherapeutic drug
concentration (< 2.5th percentile) for any of the ART
compounds (Table 2). In univariate models, the only fac-
tors associated with a decreased likelihood of subthera-
peutic drug concentrations at baseline were female
gender (P = 0.03) and nevirapine-based regimen (com-
pared with efavirenz-based regimen; P = 0.06). For all
ART compounds, the rate of subtherapeutic drug concen-
trations did not change significantly over the study per-
iod despite the intervention (P = 0.80). For efavirenz
only, there was a time trend towards fewer patients with
subtherapeutic drug concentrations after the intervention
(P = 0.08) (Table 2).
Three patients (two on efavirenz and one on lopinavir)
had comedication with rifampicin at visit 3 because of
newly diagnosed tuberculosis during the study. One of
them had an undetectable efavirenz drug concentration.
Comedications other than rifampicin (e.g. antihyperten-
sives, antibiotics, iron tablets, anti-histaminics, anti-
malarials and vitamins) were more frequent in patients
with lower drug concentrations (34.6%) compared with
those with adequate drug concentrations (22.4%;
Table 1 Baseline characteristics of the 299 study patients
Baseline characteristics
Age (years) [median (IQR)] 41 (35–48)
Sex, male [n (%)] 86 (28.8)
Pregnant [n (%)] 7 (2.3)
Distance from clinic [n (%)]*
< 5 km 218 (72.9)
5–50 km 56 (18.7)
> 50 km 24 (8.0)
Marital status [n (%)]
Married 137 (45.8)
Not married 162 (54.2)
Education [n (%)]*
None 27 (9.1)
Primary school 252 (84.6)
Secondary school or higher 19 (6.3)
Occupation [n (%)]
Employed 32 (10.7)
Farmer 256 (85.6)
Other (e.g. unemployed) 11 (3.7)
AIDS-defining diseases (WHO stage III/IV) in the past [n (%)]
Tuberculosis 91 (30.4)
Cryptoccocus 4 (1.3)
Kaposi sarcoma 8 (2.7)
Reason for starting ART*
CD4 < 200 cells/ll and/or WHO stage IV
[n (%)]
194 (65.1)
CD4 < 350 cells/ll and/or WHO stage III
[n (%)]
95 (31.9)
Time from ART initiation to start of study
(months) [median (IQR)]
43 (22–64)
ART regimen [n (%)]**
Efavirenz-based 200 (66.9)
Nevirapine-based 73 (24.4)
Lopinavir/ritonavir-based 26 (8.7)
Atazanavir/ritonavir-based 0 (0.0)
Backbone tenofovir + emtricitabine 135 (45.2)
Backbone zidvoduine + lamivudine 164 (54.8)
One-pill regimen (EFV + TDF + FTC or 3TC) 110 (36.8)
ART toxicity at baseline visit [n (%)] 3 (1.0)
Comedication [n (%)]
Cotrimoxazole prophylaxis 125 (41.8)
Other drugs 66 (22.1)
WHO stage at baseline visit [n (%)]
Stage I/II 122 (40.8)
Stage III/IV 177 (59.2)
Clinical/laboratory data [mean (SD)]
BMI (kg/m2) 23.2 (4.5)
Blood pressure systolic/diastolic (mmHg) 122/76 (20.2/12.6)
White blood cells (9109/l) 5.4 (1.6)
Haemoglobin (g/dl) 12.1 (1.8)
Alanin aminotransferase (ALAT) (IU/l) 21.9 (15.2)
Serum creatinine (lmol/l) 58.5 (22.0)
History of self-reported nonadherence prior to study
Patients with ≥ 1 previous episode of ≥ 1
missed ART dose [n (%)]
73 (24.4)
Absolute CD4 count (cells/ll) [median (IQR)]
At HIV diagnosis 174 (75–319)
Nadir 138 (59–220)
ART, antiretroviral therapy; BMI, body mass index; IQR, interquartile
range; WHO, World Health Organization. *One patient had missing data.
**Prescribed ART dosages were as follows: efavirenz (EVF) 600 mg once
daily, nevirapine 200 mg twice daily, lopinavir/ritonavir 400 mg/100 mg
twice daily, atazanavir/ritonavir 300 mg/100 mg once daily, tenofovir
disoproxil fumarate (TDF) 300 mg once daily, emtricitabine (FTC) 200 mg
once daily, lamivudine (3TC) 300 mg once daily or 150 mg twice daily,
and zidovudine 300 mg twice daily.
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P = 0.04); however, no significant drugdrug interac-
tions with ART could be identified.
CD4 cell count and HIV viral load
The median CD4 cell count was 413 (IQR: 268–610) cells/
ll at baseline, and increased significantly over time by
91 cells/ll to 504 cells/ll at visit 3 (P < 0.001 for the
comparison of visit 1 with visit 3). Immunological failure
was observed in 43 patients (14.4%) at baseline. The odds
of immunological failure decreased over time (odds ratio
0.75; P = 0.002) (Table 2). Of the 53 patients with
immunological failure at visit 1 and/or visit 2, only eight
patients were switched to a second-line treament with
lopinavir or atazanavir.
Twenty-three patients (7.7%) demonstrated virological
failure, with HIV RNA ≥ 1000 copies/ml, at baseline
(Table 2). Independent of the ART regimen, there was no
significant change in the virological failure rate observed
over time despite the intervention (odds ratio 1.09;
P = 0.50). Of the 39 patients with virological failure at
visit 1 and/or visit 2, five patients were switched to a sec-
ond-line ART regimen with lopinavir or atazanavir
because of concurrent immunological failure.
Table 2 Adherence assessment and outcome measures over the study period
Visit 1 Visit 2 Visit 3 P values
Self-reported adherence assessed using questionnaire n = 299 n = 291 n = 280
≥ 1 ART dose missed in last 4 weeks [n (%)] 10 (3.3) 31 (10.7) 16 (5.7) V1 vs. V2: P < 0.001*
V1 vs. V3: P = 0.200*
V2 vs. V3: P = 0.016*
≥ 2 ART doses missed in last 4 weeks [n (%)] 2 (0.7) 16 (5.5) 11 (3.9) V1 vs. V2: P = 0.001*
V1 vs. V3: P = 0.013*
V2 vs. V3: P = 0.300*
≥ 2 consecutive ART doses missed in last 4 weeks (n (%)] 1 (0.3) 8 (2.7) 9 (3.2) V1 vs. V2: P = 0.020*
V1 vs. V3: P = 0.011*
V2 vs. V3: P = 0.808*
Adherence assessment by TDM of ART: subtherapeutic
drug concentrations†
n = 294 n = 275 n = 255
All ART compounds [n (%)] 19 (6.5) 20 (7.3) 12 (4.7) V1 vs. V3: P = 0.800*
Efavirenz‡ [n (%)] 17 (8.7) 12 (6.7) 7 (4.2) V1 vs. V3: P = 0.080§
Nevirapine¶ [n (%)] 1 (1.4) 4 (5.9) 1 (1.7)
Lopinavir** [n (%)] 1 (4.0) 3 (12.0) 3 (15.0)
Atazanvir†† [n (%)] NA 1 (33.3) 1 (11.1)
HIV viral load n = 297 n = 286 n = 284
HIV RNA ≥ 1000 copies/ml [n (%)] 23 (7.7) 26 (9.1) 26 (9.2) V1 vs. V3: P = 0.500‡‡
CD4 cell count n = 298 n = 285 n = 275
Absolute CD4 count (cells/ll) [median (IQR)] 413 (268–610) 464 (313–630) 504 (329–647) V1 vs. V3: P < 0.001§§
CD4 percentage [median (IQR)] 21 (14–21) 22 (16–29) 22 (17–29)
Immunological failure [n (%)] 43 (14.4) 31 (10.9) 24 (8.7) V1 vs. V3: P = 0.002‡‡
Clinical outcome for all visits n = 299
Unfavourable outcome, cumulative [n (%)] 15 (5.0) NA
AIDS-defining disease¶¶ [n (%)] 6 (2.0) NA
Death*** [n (%)] 6 (2.0) NA
Loss to follow-up††† [n (%)] 3 (1.0) NA
NA, not applicable; V1, visit 1; V2, visit 2; V3, visit 3; IQR, interquartile range; TDM, therapeutic drug monitoring; ART, antiretroviral therapy. *McNemar
test. †Subtherapeutic drug concentration was defined as any concentration below the 2.5th percentile of published population-based pharmacokinetic
models for efavirenz [41], nevirapine [42], lopinavir/ritonavir [43] and atazanavir/ritonavir [44]. ‡Efavirenz: n = 196, 179 and 168 at visits 1, 2 and 3,
respectively. §Chi-squared trend analysis. ¶Nevirapine: n = 73, 68 and 58 at visits 1, 2 and 3 respectively. **Lopinavir: n = 25, 25 and 20 at visits 1, 2
and 3, respectively. ††Atazanavir: n = 0, 3 and 9 at visits 1, 2 and 3, respectively. ‡‡Repeated measures logistic regression.§§Paired Wilcoxon rank test.,
¶¶Four patients with tuberculosis and two with Kaposi sarcoma. ***One patient died because of tuberculosis (not counted in AIDS-defining
diseases).†††Did not return to clinic for visits 2 and 3.
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Fig. 2 Percentage of patients with self-reported nonadherence to
antiretroviral therapy (ART) assessed using the questionnaire at each
study visit. The y-axis shows the percentage of patients with self-
reported nonadherence.
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In a sensitivity analysis including only the 242 patients
with complete evaluations at all three visits (excluding all
patients who missed visit 2 or 3; Fig. 1), very similar
results were obtained (data not shown).
Test agreement between self-reported adherence
assessed using the questionnaire, plasma ART
therapeutic drug monitoring and virological failure
Test agreement between adherence assessed using the
questionnaire and subtherapeutic ART drug concentration
measurements was moderate to weak and differed over
the three visits and depending on the definition of self-
reported nonadherence (Table 3). The highest agreement
was found at visit 2 when nonadherence was defined as
at least two missed ART doses or at least two missed con-
secutive ART doses in the last 4 weeks (j 0.11 and 0.18;
both P < 0.05). Virological failure (HIV RNA ≥ 1000
copies/ml) was significantly correlated with subtherapeu-
tic ART drug concentration across all three visits
(j 0.329; P < 0.0001) but not with self-reported nonad-
herence assessed using the questionnaire (j 0.0614 to
0.0099) (Table 3).
Discussion
Interventional studies with the goal to specifically
improve adherence in HIV-infected patients in low-
income countries are rare [11,12]. Our intervention aimed
to enhance health care providers’ ability to encourage
HIV-infected patients to talk about adherence problems,
which is a unique approach for sub-Saharan Africa. We
demonstrated that “patient-centred” communication can
be taught within a limited period of time without the
need for a month-long run-in phase as proposed by other
authors [27,31,32,46,47], and substantially contributed to
improving adherence assessment in a rural HIV clinic in
Tanzania. Remarkably, the adherence and virological
response rate, which was greater than 90% in our selected
study population on ART at the beginning of the study,
was excellent.
As an objective method to measure adherence, we used
TDM of ART compounds, because self-reported adherence
assessment is frequently inaccurate when not properly
performed, with the consequence of missing patients with
nonadherence. The value of TDM in assessing mainly
short-term adherence has been shown in various studies
[48–52]. The high adherence rate in our study using this
measurement contrasts with other studies from sub-
Saharan Africa [6–9], in which the adherence rate, mainly
assessed using patients’ self-reported adherence, was
found to be on average only 70%. Possible explanations
for the high adherence rate in our study include a sur-
vivor treatment bias in our selected study population and
the well-organized and well-staffed CDCI.
The low virological failure rate of only 7.7% at base-
line using the HIV RNA cut-off of ≥ 1000 copies/ml pro-
posed by WHO is in line with multiple studies indicating
that HIV infection can be very effectively treated in
resource-limited countries [53–55]. With a lower cut-off
of ≥ 500 copies/ml, the failure rate was similar (9.1%;
data not shown).
Assessment of self-reported adherence revealed that
only a small minority of the patients (3.3%) disclosed any
adherence problems to the physicians at baseline, com-
pared with a nonadherence rate of 6.9% as measured by
TDM. The results of our study indicate that a patient-
centred communication approach has a significant impact
on the ability of the health care provider to elicit patients’
reports of nonadherence (3-fold increase in self-reports of
nonadherence at visit 2). However, the effect of the com-
munication training seemed to decline over time, as mea-
sured after 6–9 months, although the significance
depended on the cut-off used to define nonadherence.
Adherence assessment, which is the first, fundamental
step towards improving adherence, is challenging and
may be inaccurate [56–58]. Studies mainly from high-
income countries have shown that patient-centred com-
munication improves adherence and outcome by estab-
lishing a trusting and respectful patienthealth care
provider relationship [28–30,59]. In sub-Saharan Africa,
doctor-centred concepts are still more commonly used.
However, interpersonal interactions with health care pro-
viders are of central importance across different cultural
settings, including African countries [31,60,61], suggest-
ing that a patient-centred approach is also likely to
improve the quality of health care in resource-limited
countries.
No clear impact of our intervention on patients’ adher-
ence assessed using TDM and virological response rate
over time was shown. This may be explained by our
sample size, which was too small in the setting of unex-
pectedly high baseline adherence and virological sup-
pression rate. The target population of our study was
patients on ART for ≥ 6 months (median 3.5 years), and
therefore a survivor treatment bias could have led to
selection of the most adherent patients. We tried to mini-
mize the selection bias by enrolling all consecutive HIV-
infected patients presenting at the HIV-clinic fulfilling
the inclusion criteria. In addition, viral load results were
not available during the study in a timely fashion for
logistical reasons, impeding the ability of physicians
to adapt ART appropriately in the case of virological
failure.
© 2017 The Authors HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2017)
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Interestingly, we noted a significant decrease in the
number of patients with immunological failure and an
increase in the median CD4 cell count over time. Further-
more, although it was not significant, there was a trend
towards higher drug concentrations in the subgroup of
patients treated with efavirenz, the most commonly pre-
scribed ART drug.
Further limitations include the following. (1) Our study
was designed without a control group, that is, patients
treated by health care providers not trained in basic com-
munication skills. A control group was not included in
view of ethical considerations and the risk of a contami-
nation bias in a clinic where all health care providers
work closely together. To minimize a potential Hawthorne
effect, we compared self-reported adherence at post-inter-
vention visits with that at the baseline visit before the
intervention. (2) ART drug concentration measurements
were compared with published mixed-population based
pharmacokinetic models (mainly for Caucasians), which
could have influenced the interpretation of drug concen-
trations in an exclusively African population. However,
our cut-off (< 2.5th percentile) was set at a very low level
which probably allowed discrimination between patients
with good and those with insufficient ART intake. (3) Test
agreement between adherence assessed using the ques-
tionnaire and subtherapeutic ART drug concentration
measurements was rather low, which suggests that self-
reports of adherence might frequently be inaccurate. This
is in line with the recent FEM-PrEP study [62], in which
rates of reports of nonadherence were very low compared
with drug concentration measurements in an African set-
ting. It is noteworthy that the inter-test agreement in our
study was best after the communication training at visit
2, supporting the conclusion that the effect of the com-
munication training increased the validity of self-reports.
Our study also has several strengths. (1) Our study was
prospective with a unique intervention targeting the
important issue of adherence in a rural sub-Saharan Afri-
can clinic. (2) Our intervention was intentionally kept
simple and consisted of a short course of communication
training and an easy-to-apply adherence assessment
reminder checklist, making such an intervention feasible
and appealing for use in other resource-limited countries.
(3) We used examiner-independent TDM, which allowed a
more reliable estimation of adherence.
In conclusion, our study results indicate that a simple
intervention with a short course of training in basic
patient-centred communication for health care providers
is successfully applicable in rural sub-Saharan Africa and
has significant benefits in empowering HIV-infected
patients to talk about their adherence problems. However,
the findings suggest that health care providers need to be
repeatedly trained in view of a loss of the training effect
over time. This may be achieved, for example, by online
teaching or repeated short training sessions delivered by
dedicated local staff [47,63,64].
With the aim of achieving the goal of the “90-90-90”
Joint United Nations Programme on HIV/AIDS (UNAIDS)
to significantly reduce the HIV epidemic, ART coverage is
to be scaled up rapidly in the near future [65], with more
than 20 million HIV-infected patients to be started on
ART until 2020, most of them living in sub-Saharan
Africa. Efforts and interventions to improve and maintain
Table 3 Test agreement between adherence questionnaire, thera-
peutic drug monitoring and viral load measurements
Visit j P-value
Self-reported adherence and therapeutic drug monitoring
Adherence questions
and subtherapeutic
drug concentrations*
Missed ≥ 1
ART dose in
last 4 weeks
V1 0.047 0.80
V2 0.079 0.09
V3 0.022 0.36
Missed ≥ 2
ART doses in
last 4 weeks
V1 0.013 0.65
V2 0.110 0.03
V3 0.052 0.20
Missed ≥ 2
consecutive
ART doses in
last 4 weeks
V1 0.007 0.60
V2 0.180 < 0.001
V3 0.058 0.17
Self-reported adherence and viral load
Adherence questions
and HIV RNA ≥
1000 copies/ml
Missed ≥ 1 ART
dose in
last 4 weeks
V1–3 0.002 0.48
Missed ≥ 2
ART doses in
last 4 weeks
V1–3 0.010 0.37
Missed ≥ 2
consecutive
ART doses in
last 4 weeks
V1–3 0.061 0.73
Viral load and therapeutic drug monitoring
HIV RNA ≥ 1000 copies/ml and
subtherapeutic drug concentrations*
V1 0.385 < 0.0001
V2 0.251 < 0.0001
V3 0.359 < 0.0001
V1–V3 0.329 < 0.0001
ART, antiretroviral therapy; V1, visit 1; V2, visit 2; V3, visit 3. *< 2.5th
percentile of published population-based pharmacokinetic models.
Fig. 3 Plasma concentrationtime plots for different antiretroviral therapy (ART) drugs. (a) Plasma concentrationtime plots for patients
receiving 600 mg efavirenz once daily for all three study visits. (b) Plasma concentrationtime plots for patients receiving 200 mg nevirapine
twice daily for all three study visits. (c) Plasma concentrationtime plots for patients receiving 400/100 mg lopinavir/ritonavir twice daily for
all three study visits. The y-axis has a logarithmic scale. Circles represent patient samples. The dashed line represents the 2.5th percentile con-
centration curve derived from published population-based pharmacokinetic models (efavirenz [41], nevirapine [42] and lopinavir [43]). Concen-
trations of ART drugs below the 2.5th percentile are considered subtherapeutic. Circles on the x-axis represent patient samples with drug
concentrations below the lower limit of quantification or undetectable.
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patients’ adherence, which is critical for the success of
scaling up ART, have to be reinforced. Implementing
patient-centred communication, as shown in our study,
may contribute to the achievement of better adherence in
resource-limited countries.
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